Objective: The need for pediatric antifungal stewardship programs has been driven by an increasing consumption of antifungals for prophylactic and empirical use. Drivers and rational of antifungal prescribing need to be identified to optimize prescription behaviors.

Methods: A prospective modified weekly Point Prevalence Survey capturing antifungal prescriptions for children (> 90 days to < 18 years of age) in 12 centers in England during 26 consecutive weeks was performed. Demographic, diagnostic and treatment information was collected for each patient. Data were entered into an online REDCap database.

Results: One thousand two hundred fifty-eight prescriptions were included for 656 pediatric patients, 44.9% were girls, with a median age of 6.4 years (interquartile range, 2.5–11.3). Most common underlying condition was malignancy (55.5%). Four hundred nineteen (63.9%) received antifungals for prophylaxis, and 237 (36.1%) for treatment. Among patients receiving antifungal prophylaxis, 40.2% did not belong to a high-risk group. In those receiving antifungal treatment, 45.9%, 29.4%, 5.1% and 19.6% had a diagnosis of suspected, possible, probable and proven invasive fungal disease (IFD), respectively. Proven IFD was diagnosed in 78 patients, 84.6% (n = 66) suffered from invasive candidiasis and 15.4% (n = 12) from an invasive mold infection. Liposomal amphotericin B was the most commonly prescribed antifungal for both prophylaxis (36.6%) and empiric and preemptive treatment (47.9%). Throughout the duration of the study, 72 (11.0%) patients received combination antifungal therapy.

Conclusions: Antifungal use in pediatric patients is dominated by liposomal amphotericin B and often without evidence for the presence of IFD. A significant proportion of prophylactic and empiric antifungal use was seen in pediatric patients not at high-risk for IFD.

Key Words: antifungals, stewardship, prescriptions, children, amphotericin B, azoles

Accepted for publication September 27, 2021
From the *Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom; †Te George’s University Hospitals NHS Foundation Trust, London, United Kingdom; ‡Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children, London, United Kingdom; §The University of Queensland Centre for Clinical Research, Brisbane, Australia; †Department of Paediatric Oncology, Royal Marsden Hospital, Downs Road, Sutton, London, United Kingdom; ‡Department of Infectious Diseases and Immunology, Evelina Children Hospital, London, United Kingdom; ††Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; †‡Department of Paediatric Immunology, Infectious Diseases and Allergy, Great North Children’s Hospital, Newcastle upon Tyne; †§Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; †‖Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; §§Department of Paediatric Infectious Diseases, University Hospital Southampton NHS Foundation Trust, United Kingdom; †††Dept. of Paediatric Haematology and Oncology, Leeds General Infirmary, Leeds, United Kingdom; †‡‡Department of Paediatric Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom; and ††††Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust and Section of Paediatrics, Department of Infectious Diseases, Imperial College, London, United Kingdom.

A.W. and L.F.-A. are supported by the MRC Centre for Medical Mycology (grant MK/0046364/2). The study was funded by a clinical fellowship award from Gilead Sciences.

The authors have no conflicts of interest to disclose.

Address for correspondence: Adilia Warris, MD, PhD, MRC Centre for Medical Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, EX4 4QD, Exeter, United Kingdom. Email: a.warris@exeter.ac.uk.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ISSN: 0891-3668/22/4103-0e69
DOI: 10.1097/INF.00000000000003402

The Pediatric Infectious Disease Journal • Volume 41, Number 3, March 2022

www.pidj.com | e69
Study Definitions
A patient was defined at high-risk for IFD if they suffered from any of the following: acute myeloid leukemia, relapsed acute myeloid leukemia, relapsed acute lymphoid leukemia, severe aplastic anemia, chronic granulomatous disease, severe combined immunodeficiency or had received a hematopoietic stem cell transplant (HSCT). IFD was classified as possible, probable and proven based on the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. Antifungal use included both prophylaxis and treatment. Treatment was defined as empiric (fever driven), preemptive (diagnostic driven) and targeted (evidence for IFD). The presence of the following risk factors were collected: central venous catheter, receipt of chemotherapy, corticosteroids > 0.3 mg/kg/d, other immunosuppressive therapy, persistent neutropenia (neutrophils < 0.5 × 10^9/L for ≥ 10 days), use of broad-spectrum antibiotic (eg, piperacillin-tazobactam, meropenem, third- or fourth-generation cephalosporins, amoxicillin/clavulanic acid) for ≥ 5 days, parenteral nutrition, abdominal surgery, graft-versus-host disease, known Candida spp. colonization within 2 weeks before inclusion. Changes in dose, dosing regimen or route of administration were counted as separate prescriptions. The proportion of patients on antifungals per ward was calculated from the total of admissions at each individual ward during the successive PPS.

Data Collection
Demographic, diagnostic and treatment information were collected for each patient. Changes in the certainty of the IFD diagnosis and the antifungal prescriptions were captured while the patient was hospitalized. Data were collected via REDCap (Research Electronic Data Capture, Vanderbilt University, Nashville, TN), a web-based application in which the investigators of the participating hospitals entered data online.

Statistical Analysis
The quantitative variables were expressed as mean ± SD when they followed a normal distribution, or as median and interquartile range (IQR) when they had a non-normal distribution. Categorical variables were reported as frequency of distribution or rates and expressed as 2 × 2 tables. The distribution of factors by category of risk for IFD and the changes on treatment were analyzed using the χ^2/Fisher tests or ANOVA test according to variable characteristics. Estimates were displayed using 95% confidence intervals. The statistical significance was defined as P < 0.05. All statistical analyses were performed using Stata SE software version 14.0.

RESULTS
Nine hundred and nineteen children > 90 days old were included. Patients admitted to neonatal wards (n = 6) and those being prescribed oral nystatin only (n = 257), were excluded from the analysis. The remaining 656 patients were included. Each weekly PPS involved a mean of 100 ± 10 patients (SD 10). Each individual patient was included in the study for a median of one PPS week (IQR, 1–3). 9.8% (64/656) of the children were included in the PPS for ≥ 8 weeks, and 4.4% (29/656) ≥ 12 weeks.

Demographics and Underlying Condition
Median age was 6.4 years (IQR, 2.5–11.3). The most common underlying condition was malignancy, n = 364 (55.5%). Seventy patients (10.7%) were diagnosed with a primary immunodeficiency (PID) and 209 (31.9%) had other underlying conditions or were previously healthy children (Table 1). Of the 656 children, 419 (63.9%) received antifungals for prophylaxis, and 237 (36.1%) received antifungals for treatment at inclusion. Patients with PID and HSCT recipients received a higher proportion of antifungal prophylaxis compared with antifungal treatment (13.1% vs. 6.3% and 34.6% vs. 13.9%, respectively, P < 0.01) (Table 2).

Most children receiving antifungals for therapeutic purposes had no diagnosis of IFD, 45.9% (95% CI, 41.5%–50.3%). Of those with a diagnosis of IFD, 29.4% (95% CI, 26.3%–32.5%) had a possible, 5.1% (95% CI, 3.4%–6.8%) probable and 19.6% (95% CI, 17.2%–21.9%) proven IFD. Among the children with a proven IFD for which microbiologic data was provided (n = 78), invasive candidiasis was diagnosed in 66 (84.6%), invasive aspergillosis in 5 (6.4%) and other invasive mold infections in 7 (9.0%). Of the patients who were started on antifungal treatment at inclusion (n = 237), only 25 (10.6%) had a change in the certainty of the IFD diagnosis within the successive weeks.

| TABLE 1. Characteristics of the Study Population |
|-----------------|-----------------|-----------------|
| Patients (n)    | 656             |
| Age (y)         | 6.4 y (IQR, 2.5–11.3) |
| Sex, female     | 293 (44.9%)     |
| Underlying conditions, n (%) | 364 (55.5%) |
| Malignancy      | 85 (25.5%)     |
| ALL             | 68 (18.8%)     |
| Relapsed ALL    | 60 (16.8%)     |
| Relapsed AML    | 18 (4.4%)      |
| Other leukemias | 25 (6.9%)      |
| Non-Hodgkin lymphoma | 22 (6.1%) |
| Hodgkin lymphoma | 4 (1.1%)       |
| Solid tumors    | 80 (20.2%)     |
| Not specified   | 4 (1.1%)       |
| Underlying condition PID | 70 (10.7%) |
| (SCID)          | 25 (35.7%)     |
| Chronic granulomatous disease | 12 (17.2%) |
| Chronic mucocutaneous candidiasis | 1 (1.4%) |
| Other types of PID | 32 (45.7%) |
| Underlying condition “other” | 207 (31.6%) |
| Hematologic disorder without bone marrow suppression | 30 (14.6%) |
| Congenital heart disease (surgical) | 24 (11.7%) |
| SOT             | 19 (9.2%)      |
| CF              | 17 (8.3%)      |
| Disorder with bone marrow suppression | 14 (6.8%) |
| Gastrointestinal disease | 14 (6.8%) |
| Surgical abnormality/condition | 13 (6.3%) |
| None            | 12 (5.8%)      |
| Post-HSCT       | 12 (5.8%)      |
| Other†          | 52 (25.1%)     |
| Risk factors, n (%) |        |
| CV C            | 501 (76.4)     |
| Chemotherapy    | 328 (50.0)     |
| Broad-spectrum antibiotic (≥ 5 d) | 267 (40.7) |
| Peritransplant (HSCT or SOT) | 197 (30.0) |
| Prolonged neutropenia (≥ 10 d) | 191 (29.1) |
| Immunosuppressive therapy (nonchemotherapy) | 174 (26.5) |
| Steroid treatment (dose >0.3 mg/kg/d) | 107 (16.3) |
| Parenteral nutrition | 89 (13.8) |
| Candida colonization | 68 (10.4) |
| Abdominal surgery | 52 (7.9) |
| GVHD            | 38 (5.8)       |

*No underlying condition reported in 15 patients.
†Categories with < 10 patients in each group, including inborn errors of metabolism, nonsurgical heart disease; chronic renal disease; chromosomal/single gene disorder; chronic neurologic condition, rheumatologic or inflammatory condition; neurosurgical abnormality; chronic respiratory disease; chronic endocrinologic disease.
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Empiric treatment (n = 107) was the most common type of treatment, 29.9% (95% CI, 21.3%–38.5%) were for prophylaxis, 70.7% (95% CI, 62%–79.5%), with the majority of the patients being admitted to hematology-oncology wards (n = 313; 47.7%), followed by HSCT wards (n = 130, 19.8%) and pediatric intensive care unit (PICU; n = 88, 13.4%). The proportion of admitted children receiving antifungals was highest on the HSCT wards: 59.8% (95% CI, 56.5%–63.2%), followed by hematology-oncology wards: 38% (95% CI, 36.3%–40.3%), and PICU: 17.6% (95% CI, 15.5%–19.7%).

Most patients receiving antifungals had at least one risk factor for IFD (n = 629, 95.9%). A single risk factor was reported in 95 patients (14.5%), 2 in 136 (20.7%), and ≥ 3 in 398 (60.7%) (Table 1).

Among the patients receiving antifungal prophylaxis, 40.2% did not belong to a high-risk group, with 71.4% of the non-high-risk group having ≥ 2 risk factors. Among the non-high-risk patients receiving empiric treatment, 72.6% had ≥ 2 risk factors (Table 3).

**Ward of Admission**

The majority of the patients were admitted to hematology-oncology wards (n = 313; 47.7%), followed by HSCT wards (n = 130, 19.8%) and pediatric intensive care unit (PICU; n = 88, 13.4%). The proportion of admitted children receiving antifungals was highest on the HSCT wards: 59.8% (95% CI, 56.5%–63.2%), followed by hematology-oncology wards: 38.3% (95% CI, 36.3%–40.3%), and PICU: 17.6% (95% CI, 15.5%–19.7%).

**Antifungal Prescriptions**

The total number of prescriptions was 1258. Most prescriptions were for prophylaxis, 70.7% (95% CI, 62%–79.5%), with 29.3% (95% CI, 20.5%–38%) for treatment. Among the different types of treatment, 29.9% (95% CI, 21.3%–38.5%) were for empiric treatment; 57.4% (95% CI, 46.2%–68.5%) for preemptive treatment and 12.8% (95% CI, 8.2%–17.3%) for targeted treatment.

Liposomal amphotericin B (L-AmB) was the most commonly prescribed antifungal (n = 474, 37.7%), followed by mold-active azoles (n = 459, 36.5%). Of the mold-active azoles, itraconazole was prescribed most commonly (n = 265, 49.2%) (Table 4).

The 2 most common agents prescribed for prophylaxis were L-AmB (n = 275 prescriptions, 36.6%) and itraconazole (n = 260 prescriptions, 34.6%). Most of the L-AmB prescriptions for prophylaxis were in patients with an underlying malignancy (170/275 (61.8%)). Of the patients who were on L-AmB prophylaxis (n = 192) or itraconazole (n = 177), 66.1% (127/192) and 74.6% (132/177), respectively, were at high-risk for IFD. Prescriptions for fluconazole prophylaxis (n = 81) were mainly observed in non-high-risk patients (64/81; 79.0%), including those with non-high-risk malignancies (n = 23) and SOT recipients (n = 14).

L-AmB was the antifungal of choice for either empiric [89/189 (47.1%)] or preemptive treatment [84/172 (48.8%)]. Interestingly, the second most commonly prescribed antifungal agent for empiric treatment was fluconazole (46/189, 24.3%) to predominantly non-high-risk patients (42/46, 91.3%).

When comparing the total prescriptions for prophylaxis and empiric treatment (Table 4) with those prescribed to patients with underlying malignancies and HSCT only (Table 5), differential prescription behaviors were noted. The high-risk patients presented a higher proportion of itraconazole prophylaxis prescriptions compared with the total cohort (41.6% vs. 34.6%); whereas the proportion of fluconazole prophylaxis was lower (1.1% vs. 11.3%). Analysis of the prescriptions for empiric treatment showed a higher proportion of high-risk patients received L-AmB compared with the whole cohort (56.8% vs. 47.1%). Fluconazole was rarely prescribed as empiric treatment to high-risk patients (4.9%).

**Combination Therapy**

At inclusion, 47 (7.2%) children received combination therapy with 2, and one child with 3 antifungals. Throughout the duration of the study, a total of 72 (11.0%) patients received dual, and 2 (0.3%) received triple antifungal therapy. Of those on combination therapy, 58 (78.4%) were patients at high-risk for IFD. Combination therapy accounted for 108 prescriptions, of which 33 (30.9%) were prescriptions for proven or probable IFD, whereas 31 (29.0%) and 44 (40.2%) were in patients with possible and no diagnosis of IFD.

**Prescription Changes**

During the successive PPS weeks, 509 changes were made to prescriptions affecting 259 (39.5%) patients. Of those, 311 (61.1%) changes were deescalation measures, either a switch from intravenous to oral or from combination therapy to monotherapy. A total of 155 (30.4%) were related to a change from treatment to prophylaxis (stepping-down). The rational for those changes were either based on clinical judgment (75.6% in deescalation and 91.6% for

**TABLE 2. Rationale for Antifungal Prescription Grouped by Underlying Condition**

| Underlying condition,* N (%) | Prophylaxis, n = 419 | Treatment, n = 237 | P value | Total, n = 656 |
|-----------------------------|----------------------|-------------------|---------|----------------|
| Malignancy                  | 230 (54.8)           | 134 (56.5)        | 0.664   | 364 (55.5)     |
| Leukemia                    | 173 (41.2)           | 80 (59.8)         | 0.000   | 253 (31.4)     |
| Lymphoma                    | 15 (6.6)             | 11 (6.3)          | 0.757   | 26 (6.9)       |
| Solid organ tumor           | 38 (16.5)            | 42 (31.2)         | 0.000   | 80 (22.6)      |
| Other                       | 4 (1.8)              | 1 (0.7)           | 0.757   | 5 (1.4)        |
| HSCT recipients†            | 145 (34.7)           | 33 (13.9)         | <0.01   | 178 (27.1)     |
| Primary Immunodeficiency    | 55 (13.2)            | 15 (6.3)          | <0.01   | 70 (10.7)      |
| Others                      | 126 (30.1)           | 81 (34.2)         | 0.296   | 207 (31.6)     |

*No underlying condition reported in 15 patients.
†Irrespective of underlying condition.

**TABLE 3. Distribution of Number of Risk Factors by Rationale of Treatment: Prophylaxis and Empiric Treatment**

| Number of risk factors, n (%) | Prophylaxis (n = 418) | Empiric treatment (n = 107) |
|------------------------------|-----------------------|----------------------------|
|                              | High risk (n = 250, 59.8%) | Non-high risk (n = 168, 40.2%) | P value | High risk (n = 34, 31.8%) | Non-high risk (n = 73, 68.2%) | P value |
| None                         | 5 (2)                 | 16 (9.5)                  | <0.01   | 0 (0)                    | 0 (0)                   | <0.01   |
| 1                            | 22 (8.9)              | 32 (19.0)                 |         | 1 (2.9)                  | 20 (27.4)               |         |
| 2                            | 40 (16)               | 54 (32.1)                 |         | 1 (2.9)                  | 19 (26)                 |         |
| ≥ 3                          | 183 (73.2)            | 66 (39.3)                 |         | 32 (94.1)                | 34 (46.6)               |         |

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc. www.pidj.com | e71
stepping-down). Figure 1 shows the differentiated rational for the prescription changes made.

**DISCUSSION**

The results of this PPS show that the majority of pediatric antifungal prescriptions are for patients without evidence of IFD and that L-AmB is the most commonly used antifungal for both prophylactic and therapeutic purposes. A significant proportion of antifungal consumption was observed in pediatric patients whose underlying condition is not recognized as rendering them at high-risk for IFD. The majority of the prescriptions (70%) were for antifungal prophylaxis, which is a higher figure than previously reported in a comparable, but single PPS, showing 46% of the antifungal prescriptions to be for antifungal prophylaxis. This higher proportion seems not to be due to a larger population of children being at risk, as in our study, 40% could not be categorized as being at high-risk for IFD.

The majority of the prescriptions (70%) were for antifungal prophylaxis, which is a higher figure than previously reported in a comparable, but single PPS, showing 46% of the antifungal prescriptions to be for antifungal prophylaxis. This higher proportion seems not to be due to a larger population of children being at risk, as in our study, 40% could not be categorized as being at high-risk for IFD. The practice of defining categories of pediatric patients being at low, moderate and high risk for IFD has been used to establish management recommendations for children with hematologic malignancies and those undergoing HSCT.

For children with PID, defects in specific innate immune pathway (eg, STAT-3 deficiency), severe impairment of neutrophil function (chronic granulomatous disease) or T-cell function (severe combined immunodeficiency) are associated with a high-risk of developing IFD. For those high-risk pediatric patients, antifungal prophylaxis is recommended as antifungal prophylaxis has shown to decrease the incidence of IFD. Several studies have defined individual risk factors associated with the development of IFD. Prolonged neutropenia, the use of high-dose steroids, the presence of graft-versus-host disease, delayed lymphocyte engraftment or agents with activity against anaerobic organisms enhances the risk factors associated with the development of IFD in patients with hematopoietic disorders and IFD recipients. Central venous catheters, parenteral nutrition, the prolonged use of vancomycin or agents with activity against anaerobic organisms enhances specifically the risk of invasive candidiasis in the intensive care setting, next to those admitted to hemato-oncology wards and HSCT units. Our results reflect this specified risk to a certain extent, as fluconazole was prescribed more commonly as a prophylactic agent outside the patient population being at high-risk for IFD caused by both yeasts and molds. The combination of the underlying condition and the presence of risk factors are often taken into account when prescribing antifungal prophylaxis and empiric antifungal therapy. A number of predictive risk models for invasive candidiasis have been developed to guide antifungal therapy for children admitted to the PICU. Unfortunately, those models have either not been validated or failed to do so. Recently, a predictive risk model was developed to estimate the 60-day probability of developing probable or proven invasive mold disease in hematologic malignancy patients. Potential use of such prediction models is to allow targeted biomarker screening and fine-tuning of management strategies (eg, prophylaxis, empiric therapy) thereby optimizing antifungal prescribing. Our study showed that amongst the non-high-risk population who were on either antifungal prophylaxis or

### TABLE 4. Rationale for Prescription of Specific Antifungal Agents

| Antifungal agent | Treatment | Prophylaxis | Empiric | Preemptive | Targeted | Total |
|------------------|-----------|-------------|---------|------------|----------|-------|
| L-AmB            | High risk (n = 449) | 175 (39.0%) | 20 (37.0%) | 42 (43.3%) | 46 (56.8%) | 17 (51.5%) | 17 (51.5%) |
|                  | Non-high risk + neutropenia (n = 54) | 20 (37.0%) | 0 | 0 | 4 (4.9%) | 0 |
|                  | Solid tumors (n = 97) | 42 (43.3%) | 0 | 7 (7.2%) | 12 (14.8%) | 4 (4.9%) | 0 |
|                  | High risk (n = 81) | 17 (35.3%) | 0 | 0 | 0 | 0 |
|                  | Non-high risk + neutropenia (n = 33) | 4 (4.9%) | 0 | 0 | 0 | 0 |
|                  | Solid tumors (n = 33) | 0 | 0 | 0 | 0 | 0 |

### TABLE 5. Proportion of Prescriptions of the Different Agents as Prophylaxis or Empiric Treatment in the Groups With Underlying Malignancies and HSCT Categorized by Risk

| Antifungal agent | Prophylaxis | Empiric treatment |
|------------------|-------------|-------------------|
| L-AmB            | High risk (n = 449) | 175 (39.0%) | 20 (37.0%) | 42 (43.3%) | 46 (56.8%) | 17 (51.5%) | 17 (51.5%) |
|                  | Non-high risk + neutropenia (n = 54) | 20 (37.0%) | 0 | 0 | 4 (4.9%) | 0 |
|                  | Solid tumors (n = 97) | 42 (43.3%) | 0 | 7 (7.2%) | 12 (14.8%) | 4 (4.9%) | 0 |
|                  | High risk (n = 81) | 17 (35.3%) | 0 | 0 | 0 | 0 |
|                  | Non-high risk + neutropenia (n = 33) | 4 (4.9%) | 0 | 0 | 0 | 0 |
|                  | Solid tumors (n = 33) | 0 | 0 | 0 | 0 | 0 |

*Total prescriptions 1258, from those, 1227 with full information on rational. Other AmB: amphotericin B deoxycholate and lipids formulations of amphotericin B.
received empirical treatment, less than half of the patients had three or more risk factors. Targeting the high number of antifungal prescriptions in non-high-risk pediatric populations is needed and will be of value to improve the rational use of antifungals.

L-AmB was the most frequently prescribed antifungal for prophylaxis. This is surprising as it is not licensed for prophylaxis, efficacy data are not known, and no dosing recommendations for prophylactic use exist. Experiences with L-AmB prophylaxis are restricted to single-center reports.27,28 The compatibility with vincristine, fewer drug-drug interactions and lack of the need to perform therapeutic drug monitoring, are the most likely reasons to prescribe L-AmB instead of a mold-active azole. Some clinical management guidelines mention L-AmB as an alternative antifungal prophylaxis for pediatric patients, although with a low evidence grading due to lack of data.12,13

The European Organization for Research and Treatment of Cancer/Mycoses Study Group Consensus Definitions provide a tool to make a diagnosis of IFD with a specified level of certainty.14 It has recently undergone a second revision and the revised version captures for the first time pediatric-specific signs and symptoms.14 It should be stressed, though, that these definitions are specifically intended for the purpose of facilitating epidemiologic and clinical research and do not aim to direct patient care. Our results might indirectly demonstrate that the host factors summarized in the Consensus Definitions are being used in the decision to prescribe antifungal therapy.

L-AmB was shown to be the antifungal of choice in almost 50% of patients for empirical and preemptive therapy. Both caspofungin and L-AmB are recommended for empirical treatment in hematopoietic patients with febrile neutropenia.12,13,29 From an AFS perspective, it is critical to review empiric antifungal therapy at least weekly, as most patients on empiric therapy will not have an IFD. Preemptive antifungal therapy is a diagnostic-driven approach enabling a more targeted antifungal therapy. Our data does not reflect this differentiation in approach based on the specific antifungal prescribed and may have several explanations. Current fungal biomarkers are only available for a restricted number of fungi (eg, Candida and Aspergillus species), abnormalities on CT-chest do not identify the causative fungus, and azole-resistant aspergillosis drives the use of L-AmB if cultures are negative and susceptibility testing is not performed. Fung et al17 published a meta-analysis comparing empirical and preemptive antifungal therapy in adult patients with high-risk febrile neutropenia and reported decreased antifungal use without increasing mortality and no major economic impact when the latter strategy was used. A Cochrane review published in 2015 reported insufficient data to support a preemptive approach in children,30 and this still remains an important research gap. In the meantime, 2 single-center studies have been published supporting the use of a preemptive approach in children with febrile neutropenia.31,32

The finding of a majority of the antifungal prescriptions for pediatric patients without evidence of IFD might indirectly reflect a limitation to access available fungal diagnostics tools. We have previously reported that the use of fungal diagnostic tools varied with a prolonged turn-around time being an important barrier for many centers.33 To improve antifungal prescribing in situations where IFD is clinically suspected, efforts should be focused on the access to timely fungal diagnostics. The current indirect fungal markers (eg, β-D-glucan, galactomannan, lateral flow assay) and polymerase chain reaction-based tests are of high value to exclude the presence of IFD and are able to guide decisions to rationalize antifungal use.34

It is worth to consider the limitations of our modified PPS. While changes in diagnosis of IFD and prescriptions were captured, qualitative information such as changes in the clinical condition of the patient and diagnostics results were not collected. Prescription data was only collected when patients were admitted to the hospital, and therefore, information on the duration of antifungal prophylaxis or treatment is lacking. In addition, the impact of local guidelines was not assessed.

The Paediatric Antifungal Stewardship: Optimising Antifungal Prescription in Children modified PPS has identified key areas to be addressed in a pAFS program to optimize antifungal prescribing. The unexplained high use of antifungal prophylaxis outside the defined high-risk populations, and a significant use of antifungals as treatment in patients with suspected IFD. It reflects the challenge of recognizing who is at high risk, the difficulties encountered in either ruling in or ruling out of the presence of IFD with the current diagnostic tools, as well as timely access to fungal diagnostic tools. Further development and validation of predictive risk models in specific patient populations has the potential to more precisely define the patient at risk and to optimize antifungal use. Providing targeted educational programs and improving the access to fungal diagnostic and reporting of results are urgently needed. Establishing pAFS teams within individual centers is most likely to be of
important value to further improve rational antifungal prescription behavior as a recent single pediatric center study has shown.\textsuperscript{35}

\textbf{ACKNOWLEDGMENTS}

We are grateful for the support received at each site in the data collection and want to thank the following colleagues: John Booth (Great Ormond Street Hospital for Children, London); Lucia Van Bruggen (Royal Marsden Hospital, Sutton, London); Alicia Demirjian (Evelina Children Hospital, London); Jessy-Anne Hudson and Robin Basu Roy (Department of Paediatrics, University of Oxford, Oxford); Helen Young and Layla Campbell (Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne); Selma Eldridir Mohamed (Royal Manchester Children's Hospital, Manchester); Claire Crouch and Ruth Cantwell (Alder Hey Children's NHS Foundation Trust, Liverpool); Jessica Head (University Hospital Southampton NHS Foundation Trust, Southampton); Kirby Sinzey and Alexandria Lu (Leeds General Infirmary, Leeds); and Emily Cheshirey (Bristol Royal Hospital for Children, Bristol) and Lucia Zombori (Imperial College Healthcare NHS Trust, London).

\textbf{REFERENCES}

1. Lestner JM, Verspotten A, Doehr J, et al; ARPEC Project Group. Systemic antifungal prescribing in neonates and children: outcomes from the antibiotic resistance and prescribing in European Children (ARPEC) Study. \textit{Antimicrob Agents Chemother}. 2015;59:782–789.

2. Ferreras-Antolin L, Irwin A, Atta A, et al. Neonatal antifungal consumption is dominated by prophylactic use; outcomes from the pediatric antifungal stewardship: optimizing antifungal prescription study. \textit{Pediatr Infect Dis J.} 2019;38:1219–1223.

3. Tummey RH, Christian TE, See SK. Antifungal stewardship considerations for adults and pediatrics. \textit{Vindence}. 2017;8:658–672.

4. Pana ZD, Roilides E, Warris A, et al. Epidemiology of invasive fungal disease in children. \textit{J Pediatric Infect Dis Soc}. 2018;6:3–11.

5. Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. \textit{Clin Infect Dis}. 2018;66:140–148.

6. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. \textit{Clin Infect Dis}. 2003;36:1828–1838.

7. Fung M, Kim J, Marty FM, et al. Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia. \textit{PLoS One}. 2015;10:e0149030.

8. van der Linden JW, Arendrup MC, Warris A, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. \textit{Emerg Infect Dis}. 2015;21:1041–1044.

9. Hart E, Nguyen M, Allen M, et al. A systematic review of the impact of antifungal stewardship interventions in the United States. \textit{Ann Clin Microbiol Antimicrob}. 2019;18:24.

10. Bienvenu AL, Argaud L, Aubrun F, et al. A systematic review of interventions and performance measures for antifungal stewardship programmes. \textit{J Antimicrob Chemother}. 2018;73:297–305.

11. Whitney L, Al-Ghushein H, Glass S, et al. Effectiveness of an antifungal stewardship programme in London teaching hospital 2010-16. \textit{J Antimicrob Chemother} 2019;74:234–241.

12. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia; Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EBMT-IDWP); Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC-IDG); International Immunocompromised Host Society (ICHS); European Leukaemia Net (ELN). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. \textit{Lancet Oncol}. 2014;15:e327–e340.

13. Warris A, Lehrnbecher T, Roilides E, et al. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. \textit{Clin Microbiol Infect}. 2019;25:1096–1113.

14. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. \textit{Clin Infect Dis}. 2020;71:1367–1376.

15. Maertens J, Groll AH, Cordonnier C, et al. Treatment and timing in invasive mould infection. \textit{J Antimicrob Chemother}. 2011;66 (Suppl 1):337–43.

16. King J, Pana ZD, Lehrnbecher T, et al. Recognition and clinical presentation of invasive fungal disease in neonates and children. \textit{J Pediatric Infect Dis Soc}. 2017;6(suppl 1):S12–S21.

17. Hope WW, Castagnola E, Groll AH, et al; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. \textit{Clin Microbiol Infect}. 2012;18 Suppl 7:38–52.

18. Herbrecht R, Borios P, Moulin IC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. \textit{Ann N Y Acad Sci}. 2012;1272:23–30.

19. Czyżewski K, Gałążka P, Fraczekiewicz J, et al. Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: impact of national programme of antifungal prophylaxis. \textit{Mycoses}. 2019;62:990–998.

20. Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review. \textit{J Pediatric Infect Dis Soc}. 2018;7:191–198.

21. Hol JA, Wolfs TF, Bierings MB, et al. Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. \textit{Bone Marrow Transplant}. 2014;49:95–101.

22. Jordan I, Balaguer M, López-Castilla JD, et al; ERICAP Study Group. Per-species risk factors and predictors of invasive Candida infections in patients admitted to pediatric intensive care units: development of ERICAP scoring systems. \textit{Pediatr Infect Dis J}. 2013;32:187–193.

23. de Araujo Motta F, Dalla-Costa LM, Dominguez Muro M, et al. Risk adjustment for congenital heart surgery score as a risk factor for candidemia in children undergoing congenital heart defect surgery. \textit{Pediatr Infect Dis J}. 2017;36:1194–1198.

24. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. \textit{Clin Infect Dis}. 2010;51:e38–e45.

25. Fisher BT, Ross RK, Roilides E, et al. Failure to validate a multivariable clinical prediction model to identify pediatric intensive care unit patients at high risk for candidemia. \textit{J Pediatric Infect Dis Soc}. 2016;5:458–461.

26. Stanzani M, Vianelli N, Cavo M, et al. Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. \textit{J Infect}. 2019;78:484–490.

27. Bochennek K, Tramsen L, Scherdel N, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. \textit{Mycoology}. 2011;17:1868–1874.

28. Hand EO, Ramanathan MR. Safety and tolerability of high-dose weekly liposomal amphotericin B antifungal prophylaxis. \textit{Pediatr Infect Dis J}. 2014;33:835–836.

29. Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. \textit{J Clin Oncol}. 2017;35:2002–2094.

30. Blyth C, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. \textit{Cochrane Database Syst Rev}. 2010;2:C006343.

31. Castagnola E, Bagnasco F, Amoroso L, et al. Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hematopoietic stem cell transplant: a single center 30-year experience. \textit{Pediatr Infect Dis J} 2014;33:233–237.

32. Santolaya ME, Alvarez AM, Acuña M, et al. Efficacy of pre-emptive versus empiric antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. \textit{J Antimicrob Chemother}. 2018;73:2860–2866.

33. Ferreras-Antolin L, Sharland M, Warris A. Management of invasive fungal disease in neonates and children. \textit{Pediatr Infect Dis J}. 2019;38:2–6.

34. Schelenz S, Barnes RA, Barton RC, et al; British Society for Medical Mycology. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. \textit{Lancet Infect Dis}. 2015;15:461–474.

35. Santiago-García B, Rincón-López EM, Ponce Salas B, et al; POPA Study Group. Effect of an intervention to improve the prescription of antifungals in pediatric hematological-oncology. \textit{Pediatr Blood Cancer}. 2020;67:e27963.